BRN Ranked Now 181. S&P/ASX 200 Index Inclusion Imminent!, page-14

Yeah MSB had a similar issue too I recall. Most shareholders were excited about the inclusion until the proverbial hit the fan when the big boys started to throw it around like a rag doll.

Different kettle of fish here though… MSB were only midway through a phase 3 trial of their cellular therapy Remestemcel-L when their inclusion happened - their primary product was unproven and invalidated at the time (still no FDA approval I think?)

Akida is a proven product now and has been endorsed by major players across multiple sectors which leads me to think that while we will still be subject to the games those big institutions play, the long term result will be much more positive for us as shareholders.